Latest News on ARWR

Financial News Based On Company


Advertisement
Advertisement

Could RNAi Trial Data Alter The Investment Case For Arrowhead Pharmaceuticals (ARWR)?

https://sg.finance.yahoo.com/news/could-rnai-trial-data-alter-011037276.html
Arrowhead Pharmaceuticals (ARWR) recently reported full-year 2026 results, showing a sharp decline in revenue and a widened net loss, but also presented promising cardiometabolic RNAi data for plozasiran and ARO-DIMER-PA. The company refinanced a US$400 million term loan at a significantly lower interest rate, aiming to balance funding needs with the development of its pipeline. These developments, particularly the strong clinical data and reduced financing costs, are influencing the investment narrative as the company seeks to transition from heavy R&D spending to a commercial model.

Chardan revisits a top pick in biotech following fiscal 2026 results

https://sg.finance.yahoo.com/news/chardan-revisits-top-pick-biotech-204606763.html
Chardan analyst Keay Nakae reaffirmed a Buy rating and $115 price target on Arrowhead Pharmaceuticals (NASDAQ:ARWR) after the company reported fiscal year 2026 results and a business update. Arrowhead is one of Chardan's top picks for 2026, with developments including a supplemental New Drug Application for plozasiran targeting a Q2 2027 U.S. launch and strong prescription growth for familial chylomicronemia syndrome. The company also reported significant cash reserves and a refinanced debt facility.

Analysts Have Lowered Expectations For Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) After Its Latest Results

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/analysts-have-lowered-expectations-for-arrowhead-pharmaceuti
Following Arrowhead Pharmaceuticals' disappointing annual results, analysts have significantly lowered their revenue and earnings expectations for 2027. Revenues are now projected to decline by 32% to US$306.6m, and losses are expected to increase to US$5.53 per share, a considerable downgrade from previous forecasts. Despite the weaker outlook, the average price target remained at US$106, suggesting that analysts do not foresee a long-term impact on the company's valuation.

Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings

https://www.biospace.com/business/arrowheads-ionis-problem-kyvernas-next-gen-end-and-more-biotech-earnings
This article recaps recent biotech earnings, highlighting Arrowhead Pharmaceuticals' challenges following Ionis's disappointing Tryngolza sales in severe hypertriglyceridemia, a market Arrowhead's Redemplo is entering. It also covers Kyverna Therapeutics' decision to deprioritize a next-gen manufacturing program for its cell therapy, miv-cel, while it awaits FDA approval for stiff person syndrome. Additionally, the piece details promising catalysts for Prime Medicine in Wilson's disease and alpha-1 antitrypsin deficiency, and Cullinan Therapeutics' upcoming data readouts for autoimmune and lung cancer drugs.

Key facts: Arrowhead FY2026 Loss; Positive sHTG Data; REDEMPLO Launch

https://www.tradingview.com/news/tradingview:c8ab9139e7278:0-key-facts-arrowhead-fy2026-loss-positive-shtg-data-redemplo-launch/
Arrowhead Pharmaceuticals (ARWR) reported a significant net loss and decreased revenue for FY2026, though cash and securities remained strong. The company also announced positive Phase 3 results for severe hypertriglyceridemia (sHTG) and the launch of REDEMPLO for familial chylomicronemia syndrome (FCS). Additionally, interim Phase 1/2a data for ARO-DIMER-PA showed promising reductions in various cholesterol and triglyceride markers, and analysts anticipate substantial upside for the stock.
Advertisement

[Arrowhead Pharmaceuticals Q4 2026 Earnings Call] Arrowhead Posts $724M Net Loss as REDEMPLO Revenue Hits $6.6M; Flags $3B-$4B SHTG Opportunity and Q2 2027 Launch

https://finance.biggo.com/news/US_ARWR_2026-11-12
Arrowhead Pharmaceuticals reported a significant net loss of $724.2 million for fiscal 2026, primarily due to a one-time priority review voucher expense and the absence of prior-year collaboration revenue. Despite this, their first commercial product, REDEMPLO, generated $6.6 million, and the company is aggressively preparing for a potential Q2 2027 U.S. launch in severe hypertriglyceridemia (SHTG), projecting $3 billion-$4 billion in annual sales. Arrowhead also refinanced debt and plans to sell a transferable priority review voucher to bolster its balance sheet.

ARWR Q4 FY2026 earnings call

https://finance.biggo.com/quote/ARWR/earnings-call/US_ARWR_2026-11-12
Arrowhead Pharmaceuticals reported a net loss of $724.2 million for fiscal year 2026, primarily due to a one-time priority review voucher expense and the absence of prior year collaboration revenue, despite total revenue of $450.8 million. The company is focused on the commercialization of REDEMPLO for familial chylomicronemia syndrome (FCS) and is preparing for a potential U.S. launch in severe hypertriglyceridemia (SHTG) in Q2 2027. Key pipeline advancements include progress in zodasiran, ARO-DIMER-PA, ARO-MAPT, and obesity programs, alongside a significant debt refinancing and a change in fiscal year-end.

Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q4 EPS by 356c

https://www.streetinsider.com/Earnings/Arrowhead+Pharmaceuticals+Inc.+%28ARWR%29+Misses+Q4+EPS+by+356c/27336139.html
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported a significant miss on its Q4 EPS, coming in at ($5.11) against an analyst estimate of ($1.55), a difference of $3.56. Despite the EPS miss, the company's revenue for the quarter was $450.82 million, substantially exceeding the consensus estimate of $59.19 million. The stock experienced a 4.48% drop, trading at $47.15.

Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results

https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-reports-2026-fiscal-year-end-results
Arrowhead Pharmaceuticals announced its 2026 fiscal year-end results, highlighting significant commercial momentum for REDEMPLO® and progress in its R&D pipeline, including regulatory submissions for plozasiran in severe hypertriglyceridemia. The company also reported a strategic refinancing of its credit facility and a change in its fiscal year end. Despite a net loss attributable to Arrowhead Pharmaceuticals, Inc. of $(724,206) thousand, the company emphasized its shift from scientific promise to real patient outcomes and potential for shareholder value growth.

Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences

https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-investor-1
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced its participation in three upcoming investor conferences in November and December 2026. The company will present at the 2026 Jefferies Global Healthcare Conference, Citi’s 2026 Global Healthcare Conference, and the Piper Sandler 38th Annual Healthcare Conference. These presentations will be in a fireside chat format, with details on dates, times, and access to materials provided.
Advertisement

Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates

https://www.biospace.com/press-releases/arrowhead-pharmaceuticals-presents-plozasiran-data-highlighting-sustained-triglyceride-reductions-and-reduced-acute-pancreatitis-rates
Arrowhead Pharmaceuticals presented new data on plozasiran and ARO-DIMER-PA at the American Heart Association Scientific Sessions 2026. Plozasiran demonstrated sustained reductions in triglycerides and APOC3, and significantly reduced acute pancreatitis event rates in patients with severe hypertriglyceridemia and familial chylomicronemia syndrome. Interim results for ARO-DIMER-PA showed simultaneous suppression of PCSK9 and APOC3, leading to reductions in LDL cholesterol and triglycerides in patients with mixed hyperlipidemia.

Arrowhead reports lower pancreatitis rates, early cholesterol drug results (ARWR:NASDAQ)

https://seekingalpha.com/news/4668766-arrowhead-reports-lower-pancreatitis-rates-early-cholesterol-drug-results
Arrowhead Pharmaceuticals announced that its drug plozasiran significantly reduced rates of acute pancreatitis by 78% in late-stage studies, with a 91% reduction in patients with a history of the condition. The company also shared early positive results for ARO-DIMER-PA, an experimental treatment that showed reductions in LDL cholesterol and triglycerides. While plozasiran showed a manageable safety profile with some worsening blood-sugar control, further studies are needed to fully establish the safety and efficacy of ARO-DIMER-PA.

Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates

https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-plozasiran-data-highlighting
Arrowhead Pharmaceuticals presented data at the American Heart Association Scientific Sessions 2026 for two RNAi-based therapies, plozasiran and ARO-DIMER-PA. Plozasiran demonstrated significant reductions in acute pancreatitis event rates in patients with severe hypertriglyceridemia and sustained triglyceride lowering in those with familial chylomicronemia syndrome. Interim results for ARO-DIMER-PA showed promising dual reduction in LDL cholesterol and triglycerides in mixed hyperlipidemia patients, highlighting the potential of targeting multiple lipid pathways with a single molecule.

Arrowhead Pharmaceuticals options signal 8.1% move on earnings By Investing.com

https://au.investing.com/news/stock-market-news/arrowhead-pharmaceuticals-options-signal-81-move-on-earnings-93CH-4748742
Options data suggests Arrowhead Pharmaceuticals Inc. (ARWR) shares could move 8.1% following its upcoming earnings report on November 12. The biotech company's stock has exceeded the options-implied move in three of its last eight earnings announcements, with a notable jump of 43.7% in November 2025 against a 10.0% implied move. Options traders consistently anticipate volatility around Arrowhead's earnings releases.

Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity

https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-refinances-existing-credit-facility
Arrowhead Pharmaceuticals announced it has refinanced its $400 million credit facility with Sixth Street, which reduces borrowing costs, improves near-term liquidity, and extends debt maturity to November 2031. The new facility is priced at SOFR plus 5.50% and eliminates required prepayments or sweeps. This transaction provides greater financial and operational flexibility as the company advances its REDEMPLO® business and pipeline.
Advertisement

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results

https://www.biospace.com/press-releases/arrowhead-pharmaceuticals-to-webcast-2026-fiscal-year-end-results
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced it will host a webcast and conference call on November 12, 2026, at 4:30 p.m. ET to discuss its financial results for the 2026 fiscal year, which ended September 30, 2026. Investors can access a live audio webcast on the company's website, with a replay available afterwards, while analysts need to register to participate in the conference call. The company specializes in developing RNAi therapeutics for intractable diseases.

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results

https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-webcast-2026-fiscal-year-end-results
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced it will host a webcast and conference call on November 12, 2026, at 4:30 p.m. ET to discuss its financial results for the 2026 fiscal year, which ended September 30, 2026. Investors can access a live audio webcast on the company's website, with a replay available afterwards. Analysts wishing to participate in the conference call need to register to receive dial-in details and a personalized PIN code.

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

https://www.biospace.com/press-releases/arrowhead-pharmaceuticals-to-present-important-clinical-data-at-the-american-heart-association-scientific-sessions-2026
Arrowhead Pharmaceuticals announced it will present key clinical data at the American Heart Association Scientific Sessions 2026. The presentations will include detailed Phase 1/2a results for ARO-DIMER-PA for mixed hyperlipidemia, pooled analysis of plozasiran from SHASTA-3/4 studies for severe hypertriglyceridemia, and three-year efficacy and safety data for plozasiran in familial chylomicronemia syndrome from the PALISADE study. These presentations highlight the company's progress in developing RNAi therapeutics for lipid disorders.

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-present-important-clinical-data
Arrowhead Pharmaceuticals, Inc. announced it will present important clinical data at the American Heart Association Scientific Sessions 2026, held in Chicago. Presentations will include detailed results from the Phase 1/2a study of ARO-DIMER-PA for mixed hyperlipidemia, pooled analysis of plozasiran from SHASTA-3/4 for severe hypertriglyceridemia, and three-year data on plozasiran in familial chylomicronemia syndrome from the PALISADE study. These presentations highlight the company's advancements in RNAi therapeutics for cardiometabolic diseases.

Arrowhead Pharmaceuticals, Inc. (ARWR) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/ARWR/seasonality/
This article provides a seasonal returns chart for Arrowhead Pharmaceuticals, Inc. (ARWR) on Yahoo Finance. It displays the average monthly price return for ARWR between 2016 and 2026, allowing users to analyze historical seasonality over various periods. The page also includes current stock price data and navigation to other financial information for the company.
Advertisement

Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

https://ir.arrowheadpharma.com/news-releases/news-release-details/adults-living-familial-chylomicronaemia-syndrome-fcs-england-and
Arrowhead Pharmaceuticals announced that REDEMPLO® (plozasiran) has received Marketing Authorisation from the UK MHRA and a recommendation for funding from NICE, providing a new treatment option for adults with Familial Chylomicronaemia Syndrome (FCS) in England and Wales. This treatment, used as an adjunct to diet, aims to reduce extremely high triglyceride levels and mitigate the risk of acute pancreatitis and related complications in FCS patients. The approval is based on findings from the PALISADE study, which demonstrated plozasiran's significant efficacy in reducing fasting triglyceride levels.

Arrowhead Pharmaceuticals, Inc. Estimates – NASDAQ:ARWR

https://www.tradingview.com/symbols/NASDAQ-ARWR/financials-estimates/
This article provides an overview of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) financial data and analyst estimates available on TradingView. It directs users to explore reported financial data and compare actual results with average, high, and low estimates across various financial statements. The content emphasizes that it is not investment advice and encourages users to conduct their own research.

Arrowhead Pharmaceuticals, Inc. (0HI3.IL) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/0HI3.IL/latest-news/
This Yahoo Finance page provides an overview of Arrowhead Pharmaceuticals, Inc. (0HI3.IL) stock, including its current price, market data, and a compilation of recent news articles. The news highlights developments such as new data for ARO MAPT, comparisons with other biotech companies, and updates on its Alzheimer's drug and new drug platform. The stock is currently trading at 28.93 USD, up 3.05%.

The future of RNAi with Arrowhead’s Chris Anzalone on The BioCentury Show

https://www.biocentury.com/article/661194/the-future-of-rnai-with-arrowhead-s-chris-anzalone-on-the-biocentury-show
Chris Anzalone, CEO of Arrowhead Pharmaceuticals, discussed the future of RNAi on The BioCentury Show, focusing on solving extra-hepatic siRNA delivery and growth opportunities. He highlighted siRNA's advantages over ASOs for gene silencing and the importance of multi-tissue delivery as a platform unlock for broader RNAi applications. Expanding delivery beyond the liver to other organs is seen as critical for scaling RNAi and reducing risk.

Arrowhead Pharmaceuticals Advances Alzheimer's Drug Push With Promising Early Clinical Results

https://www.yahoo.com/news/science/articles/arrowhead-pharmaceuticals-advances-alzheimers-drug-163009031.html
Arrowhead Pharmaceuticals reported promising interim data from its Phase 1/2a trial for ARO-MAPT, an RNA interference therapy for Alzheimer's disease. The therapy successfully delivered siRNA across the blood-brain barrier, leading to significant and sustained reductions in tau protein levels in healthy participants. These early results suggest a potential for a convenient quarterly dosing schedule and a favorable safety profile, with the company now enrolling early-stage Alzheimer's patients for further evaluation.
Advertisement

Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $126

https://www.moomoo.com/news/post/1001440639/piper-sandler-maintains-arrowhead-pharmaceuticals-arwrus-with-buy-rating-maintains
Piper Sandler has reiterated its Buy rating for Arrowhead Pharmaceuticals (ARWR.US), maintaining a price target of $126. This indicates a continued positive outlook from the firm regarding the company's stock performance.

UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $109 From $63, Maintains Buy Rating

https://finance.yahoo.com/markets/stocks/articles/ubs-adjusts-price-target-arrowhead-143354189.html
UBS has increased its price target for Arrowhead Pharmaceuticals (ARWR) to $109 from $63, while reiterating a Buy rating on the stock. This adjustment comes as the average analyst rating for Arrowhead Pharmaceuticals remains a "buy" with a mean price target of $107.92. The article notes that access to the full details requires a premium subscription.

Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data drop

https://www.biospace.com/drug-development/arrowheads-blood-brain-barrier-tech-is-arguably-better-than-others-analysts-say-after-data-drop
Arrowhead Pharmaceuticals' siRNA candidate, ARO-MAPT, showed "compelling" tau reductions in an early Phase 1/2a study in healthy volunteers, outperforming other blood-brain barrier platforms, according to Stifel analysts. The investigational gene silencer achieved significant cerebrospinal fluid (CSF) tau reductions and was generally well-tolerated, suggesting a potential competitive edge over treatments like Biogen's BIIB080 due to its subcutaneous administration. While direct comparisons are cautioned due to study differences, the data provides strong clinical validation for Arrowhead's central nervous system targeting platform.

Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study

https://finance.yahoo.com/healthcare/articles/arrowhead-pharmaceuticals-reports-73-csf-230211470.html
Arrowhead Pharmaceuticals reported promising interim Phase I/II data for ARO-MAPT, an investigational RNA therapy, showing up to a 73% reduction in CSF tau in healthy volunteers. This marks the company's first clinical proof of concept for delivering siRNA to the central nervous system via subcutaneous injection. The treatment was well tolerated, and trials are continuing in early Alzheimer's disease, with potential future studies in progressive supranuclear palsy and MAPT-related frontotemporal dementia.

Arrowhead Pharmaceuticals Advances Alzheimer's Drug Push With Promising Early Clinical Results

https://www.benzinga.com/news/health-care/26/10/62363179/arrowhead-pharmaceuticals-advances-alzheimers-drug-push-with-promising-early-clinical-results
Arrowhead Pharmaceuticals announced promising early clinical results for ARO-MAPT, an investigational RNA interference therapy for Alzheimer's disease. The therapy successfully reduced tau protein levels in the central nervous system, with some participants experiencing up to a 73% reduction. The drug also demonstrated a favorable safety profile and could potentially support a quarterly dosing schedule.
Advertisement

Arrowhead stock gains on trial data for Alzheimer’s drug (ARWR)

https://seekingalpha.com/news/4652880-arrowhead-stock-gains-trial-data-alzheimers-drug
Arrowhead Pharmaceuticals (ARWR) saw its stock rise over 4% in premarket trading following positive early-stage clinical trial data for its Alzheimer's therapy, ARO-MAPT. The data provided initial clinical validation for the company's TRiM delivery platform. ARO-MAPT is an RNA interference therapeutic targeting Alzheimer's disease.

Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-aro-mapt-interim-phase-12a
Arrowhead Pharmaceuticals announced positive interim Phase 1/2a clinical data for ARO-MAPT, an RNAi therapeutic for Alzheimer's disease and other tauopathies. The study showed deep and durable reductions in cerebrospinal fluid total tau in healthy volunteers, with a mean reduction of up to 73% and a maximum of 85%. This data also validates Arrowhead's TRiM™ platform for delivering siRNA across the blood-brain barrier via subcutaneous injection, supporting the potential for quarterly dosing and further development in CNS diseases.

Arrowhead Pharmaceuticals Reports Up to 73% Tau Reduction in ARO-MAPT Trial

https://finance.yahoo.com/healthcare/articles/arrowhead-pharmaceuticals-reports-73-tau-121121667.html
Arrowhead Pharmaceuticals (ARWR) announced a significant reduction of up to 73% in cerebrospinal fluid total tau levels in its ARO-MAPT trial. This promising result suggests a potential therapeutic benefit for conditions involving tau pathology. Full details are available to premium subscribers of MT Newswires.

Why is Arrowhead Pharmaceuticals stock surging today?

https://www.investing.com/news/stock-market-news/why-is-arrowhead-pharmaceuticals-stock-surging-today-93CH-4949015
Arrowhead Pharmaceuticals stock surged by 8.4% in pre-open trading after announcing positive interim Phase 1/2a results for ARO-MAPT, a therapeutic targeting the tau protein linked to Alzheimer’s disease. The study showed a significant reduction in total tau in healthy volunteers and validated the company's TRiM™ platform for drug delivery across the blood-brain barrier via subcutaneous injection. This clinical success, combined with a reassuring safety profile, drove investor enthusiasm.

BofA Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100

https://www.moomoo.com/news/post/1000940021/bofa-securities-maintains-arrowhead-pharmaceuticals-arwrus-with-buy-rating-maintains
BofA Securities has reiterated its Buy rating on Arrowhead Pharmaceuticals (ARWR.US), maintaining a target price of $100. This continued endorsement suggests the firm's confidence in Arrowhead's future performance.
Advertisement

Arrowhead Pharmaceuticals (ARWR) Climbed Today, What Is Behind The Move?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/arrowhead-pharmaceuticals-arwr-climbed-today-what-is-behind/amp
Arrowhead Pharmaceuticals (ARWR) saw a gain after the FDA accepted its plozasiran into the STAR pilot program for severe hypertriglyceridemia, despite recent short-term share price drops. The company's stock is currently considered 43% undervalued by analysts, trading at a steep discount compared to its fair value and analyst targets. Investors are evaluating the potential of its RNAi pipeline and regulatory milestones, noting both significant long-term returns and recent volatility.

Arrowhead Flat on FDA Nod

https://www.baystreet.ca/stockstowatch/24183/Arrowhead-Flat-on-FDA-Nod
Arrowhead Pharmaceuticals (NASDAQ: ARWR) shares saw a slight increase after the FDA granted plozasiran entry into its Split Real Time Application Review (STAR) pilot program. This program is for the company's upcoming supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG), a condition increasing the risk of acute pancreatitis. Entry into the STAR program allows for an expedited six-month Priority Review for the sNDA and means Arrowhead retains its previously purchased Priority Review Voucher.

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

https://finance.yahoo.com/healthcare/articles/arrowhead-pharmaceuticals-granted-entry-fda-113000317.html
Arrowhead Pharmaceuticals announced that the FDA has granted plozasiran entry into the Split Real Time Application Review (STAR) pilot program for severe hypertriglyceridemia (sHTG). This program aims to expedite the review process for their upcoming supplemental new drug application (sNDA), potentially leading to earlier patient access to plozasiran, which is already approved in several regions for familial chylomicronemia syndrome (FCS). The company plans to submit the sNDA for sHTG by year-end 2026.

Arrowhead Pharmaceuticals (NasdaqGS:ARWR) Stock Forecast & Analyst Predictions

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/future
Arrowhead Pharmaceuticals (ARWR) is projected to grow earnings by 49.4% and revenue by 30.9% annually. Recent updates highlight the FDA's acceptance of its drug plozasiran into the STAR pilot program for severe hypertriglyceridemia, aiming for faster review, and the completion of patient enrollment for the Phase 3 YOSEMITE trial for zodasiran. The company also announced positive long-term efficacy and safety data for plozasiran across various hypertriglyceridemia patient groups.

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-granted-entry-fda-star-pilot-program
Arrowhead Pharmaceuticals announced that the FDA has granted plozasiran entry into the Split Real Time Application Review (STAR) pilot program for severe hypertriglyceridemia (sHTG). This program aims to expedite the review process for the upcoming supplemental new drug application (sNDA) for plozasiran, potentially shortening the time to patient access. Plozasiran, already approved as REDEMPLO® for familial chylomicronemia syndrome (FCS), will receive Priority Review without needing a Priority Review Voucher.
Advertisement

Arrowhead Pharmaceuticals, Inc. (ARWR) Stock forecasts

https://sg.finance.yahoo.com/research/reports/ARGUS_5148_QuantitativeReport_1790726400000
Argus has lowered its target price for Arrowhead Pharmaceuticals, Inc. (ARWR) to $63.00, down from an unspecified previous target. The biotechnology company focuses on developing medicines for genetic diseases characterized by protein overproduction. The report was published on September 30, 2026.

Arrowhead Pharmaceuticals, Inc. (ARWR) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/ARWR/
This article provides a comprehensive overview of Arrowhead Pharmaceuticals, Inc. (ARWR) stock, including its current price, historical data, key financial metrics, and analyst ratings. It details the company's drug pipeline with various RNAi therapeutics in different clinical trial phases. The report also highlights performance against the S&P 500 and lists revenue and earnings trends.

Long term debt to total equity ratio of Arrowhead Pharmaceuticals, Inc. – HAN:HDP1

https://www.tradingview.com/symbols/HAN-HDP1/financials-statistics-and-ratios/long-term-debt-to-equity/
This article focuses on the long-term debt to total equity ratio of Arrowhead Pharmaceuticals, Inc. (HDP1) on the Hannover Stock Exchange. It provides financial data related to this specific ratio, highlighting its value and change over a period. The content is presented within the context of TradingView's financial analysis tools, offering a snapshot of the company's financial health.

Free cash flow of Arrowhead Pharmaceuticals, Inc. – HAN:HDP1

https://www.tradingview.com/symbols/HAN-HDP1/financials-cash-flow/free-cash-flow/
The article provides financial information for Arrowhead Pharmaceuticals, Inc. (HAN:HDP1) on TradingView, specifically focusing on its free cash flow. It lists the company's stock exchange details and offers various financial and community features available on the platform for this particular stock.

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-host-webinar-interim-clinical-data
Arrowhead Pharmaceuticals announced a webinar on October 14, 2026, to discuss investigational therapy ARO-MAPT and its CNS pipeline. The webinar will feature interim clinical data from a Phase 1/2a study of ARO-MAPT, which is an RNAi therapeutic designed to treat tauopathies like Alzheimer’s disease by silencing the MAPT gene. ARO-MAPT uses a proprietary siRNA delivery system that can cross the blood-brain barrier for systemic delivery to the CNS.
Advertisement

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

https://finance.yahoo.com/healthcare/articles/arrowhead-pharmaceuticals-host-webinar-interim-113000043.html
Arrowhead Pharmaceuticals announced it will host an R&D webinar on October 14, 2026, to present interim clinical data from its Phase 1/2a study of ARO-MAPT. This investigational RNA interference therapeutic targets tauopathies, including Alzheimer's disease, by silencing the MAPT gene. The webinar will feature presentations from Arrowhead management and Adam Boxer, M.D., Ph.D., from UCSF, discussing the ARO-MAPT program and the company's CNS pipeline.

ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near

https://stocktwits.com/news-articles/markets/equity/arwr-stock-goldman-sachs-resumes-coverage-with-74-target-as-clinical-catalysts-near/cZM7CC9RB95
Goldman Sachs has resumed coverage of Arrowhead Pharmaceuticals (ARWR) with a 'Neutral' rating and a $74 price target, citing acquisition activity, positive clinical catalysts, and a favorable regulatory outlook for biotech stocks. The move follows Arrowhead's announcement of interim topline results from its Phase 1/2a ARO-DIMER-PA trial and progress on plozasiran toward regulatory filing. Citi also maintains a Buy rating and $108 price target, placing the stock on an "upside 30-day catalyst watch" ahead of further clinical data.

Arrowhead Pharmaceuticals Drops 5.4% Amid Sector-Wide Selling

https://news.alphastreet.com/arrowhead-pharmaceuticals-drops-5-4-amid-sector-wide-selling/amp/
Arrowhead Pharmaceuticals experienced a 5.4% drop in its stock price, closing at $67.96, as a result of a widespread selloff in the biotechnology sector. Several peer companies also saw significant declines, indicating broader market concerns rather than company-specific issues for Arrowhead. Investors are advised to monitor the overall stability of the biotechnology sector rather than focusing solely on individual stock fundamentals.

Arrowhead Pharmaceuticals Plans Supplemental Drug Approval Application

https://intellectia.ai/news/stock/arrowhead-pharmaceuticals-plans-supplemental-drug-approval-application
Arrowhead Pharmaceuticals plans to file a supplemental application for Redemplo for severe hypertriglyceridemia by year-end, with CEO Chris Anzalone projecting peak U.S. sales of $3 billion to $4 billion. Despite an initial "slow burn" launch, sales are progressing faster than expected after insurer negotiations, and the company plans further market expansion in early 2027. Arrowhead also boasts a robust pipeline, including zodasiran for a rare high-cholesterol condition, and retail investor sentiment for ARWR stock has shifted to "extremely bullish."

ARWR Stock On Track For Worst Day In Over A Year Despite Positive Early-Stage Data For Cholesterol Drug — Retail Dismisses ‘Sell The News’ Reaction

https://finance.yahoo.com/healthcare/articles/arwr-stock-track-worst-day-190342085.html
Shares of Arrowhead Pharmaceuticals (ARWR) experienced their worst day in over a year, falling more than 10% despite releasing positive early-stage human trial data for its experimental cholesterol drug, ARO-DIMER-PA. The drug showed significant reductions in "bad" cholesterol and triglycerides, but analysts suggest the selloff could be a "sell the news" reaction, as the stock had previously run up in anticipation of the catalyst. Retail investors, however, appear to be buying the dip, with sentiment shifting from bearish to bullish on platforms like Stocktwits.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement